Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply
Citation
Cipriani, Andrea; Adamo, Nicoletta; Del Giovani, Cinzia; Goghill, David; Banaschewski, Tobias; Hollis, Chris; Zuddas, Alessandro; Simonoff, Emily; Cortese, Samuele. Unbalanced risk-benefit analysis of ADHD drugs – Authors' reply. Lancet Psychiatry Correspondence 2018 5(11)P871-873
Abstract
Standardised mean differences can be difficult to translate into clinical practice. As reported in the Cochrane handbook, the mean difference (or more correctly, difference in means) measures the absolute difference between the mean value in two groups and then estimates the average amount that the experimental intervention changes in the outcome compared with that of the control intervention.
Description
Published online at: DOI: 10.1016/S2215-0366(18)30396-1
This is an Open Access article under the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
Copyright © 2018 Elsevier Ltd. All rights reserved.
Collections
- Drug Therapy [5]